ArticleEClinicalMedicine2024

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.

Min Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.